期刊
CANCER CHEMOTHERAPY AND PHARMACOLOGY
卷 63, 期 3, 页码 525-528出版社
SPRINGER
DOI: 10.1007/s00280-008-0778-7
关键词
Imatinib; CML; GIST; Interaction
资金
- University of Pittsburgh Clinical Translational Research Center
- Novartis Pharmaceuticals Corporation (East Hanover, NJ)
- NIH/NCRR/CTSA [UL1 RR024153]
Imatinib often causes gastric upset resulting in frequent co-administration of an antacid. Elevated gastric pH, delayed gastric emptying, or introduction of Mg2+/Al3+ could potentially change imatinib absorption, thereby affecting the therapeutic effectiveness of imatinib. Indeed, antacid co-administration with dasatinib does result in a twofold decrease in dasatinib absorption. We aimed to define the effect of antacid on the pharmacokinetics of imatinib. Twelve healthy subjects were enrolled in a 2-period, open-label, randomized cross-over, fixed-sequence study. In one period, each subject received 400 mg imatinib p.o., and in the other, the same dose of imatinib preceded by 20 mL antacid, containing 1.6 g Al(OH)(3) + 1.6 g Mg(OH)(2), 15 min before imatinib. Plasma concentrations of imatinib and its active N-desmethyl metabolite CGP74588 were determined by LC-MS, and data were analyzed non-compartmentally. Antacid administration did not significantly affect the area under the plasma imatinib concentration versus time curve (AUC) [31.7 mu g/(mL h) alone versus 32.6 mu g/(mL h) with antacid, P = 0.37; 80% power]. Our results indicate that the use of Mg2+-Al3+-based antacid does not significantly affect imatinib absorption.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据